Cardinal Health (NYSE: CAH) Chief Accounting Officer Mary C. Scherer sold 2,302 shares of company stock on August 19, according to an SEC Form 4 filing.
The shares were sold at a weighted-average price of $237.39 per share, generating a total transaction value of approximately $546,500 for the executive.
Following the sale, Scherer retains direct ownership of 2,811 shares, representing a stake valued at roughly $660,163 based on the August 19 market close of $234.85.
The transaction price of $237.39 came in slightly above the August 19 closing price, with the stock ending that session at $234.85 per share.
Her remaining 2,811 shares represent a tiny 0.001% stake in the company, which carries a market capitalization of $55.0 billion.
The sale reduced her total holdings by roughly 20% from 3,495 shares prior to an August 4 performance award, indicating she sold shares acquired as part of that recent compensation grant.
Several other Cardinal Health executives also sold stock during the same period, though Scherer’s August performance grant appears smaller relative to those of other senior leaders at the company.
The disposition occurred after Cardinal Health stock delivered a 58% return over the 12 months ending August 19, a strong run that may have prompted some profit-taking among company insiders.
Cardinal Health reported trailing 12-month revenue of $254.2 billion and net income of $1.7 billion as of the transaction date, reflecting its massive scale as a global healthcare services intermediary.
The company operates through two core segments, Pharmaceutical and Medical, serving hospitals, pharmacies, outpatient surgical centers, clinical laboratories, physician practices, and home care patients across multiple continents.
One notable financial detail from the company’s most recent quarterly results involves a tariff-related accounting item that investors should monitor closely going forward.
Cardinal Health booked a $100 million net operating benefit in its medical segment from tariff refunds, recognized on the expectation of collecting roughly $200 million in total refunds.
That refund contributed $0.31 to fourth-quarter earnings per share of $2.91, accounting for roughly 15 of the 40 percentage points of EPS growth reported for that quarter.
Crucially, the tariffs that replaced the ones being refunded are still generating ongoing costs for the company, meaning the benefit is one-time while the drag on earnings is not.
Long-term investors in Cardinal Health may want to watch closely how that tariff dynamic ultimately affects margins in the company’s medical segment over future reporting periods.
